Clinical course of intoxication with the new anticonvulsant drug perampanel.

Abstract

Perampanel has recently been approved as an anticonvulsant drug for focal epilepsies. Phase III trials have shown good tolerability, although data regarding effects of high doses of perampanel are not available. Here, we describe the first case of a 34-year-old patient with perampanel intoxication and attempted suicide, in which the recommended daily dose of perampanel was exceeded ten-fold. Clinical signs of the intoxication and possible psychotropic effects are described.

• Authors: Anselm C Hoppner, Susanne Fauser, Frank Kerling
• Journal: Epileptic disorders : international epilepsy journal with videotape (Epileptic Disord) Vol. 15 Issue 3 Pg. 362-4 (Sep 2013) ISSN: 1294-9361 [Print] United States
• PMID: 24001596 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticonvulsants
• Nitriles
• Pyridones
• perampanel

Topics

• Adult
• Anticonvulsants (pharmacokinetics, poisoning, therapeutic use)
• Epilepsies, Partial (complications, drug therapy, etiology)
• Epilepsy, Tonic-Clonic (drug therapy, etiology)
• Female
• Glasgow Coma Scale
• Humans
• Nitriles
• Pyridones (pharmacokinetics, poisoning, therapeutic use)
• Seizures (physiopathology)
• Suicide, Attempted
• Tuberous Sclerosis (complications)